CAR T cells engineered to secrete tumor-localized anti-EpCAM bispecific T cell engagers (BTCEs) overcome antigen escape and heterogeneity across multiple epithelial carcinomas in preclinical models, achieving complete tumor eradication where conventional single-target CAR T cell therapies often failed, supporting broad translational potential for solid tumor immunotherapy.

AAV-WM04, an AAV vector identified through in-vivo-directed screening in the adult cochlea, enables highly efficient and selective inner hair cell transduction. Dual-AAV delivery of OTOF using AAV-WM04 restores hearing in a DFNA9 deafness mouse model at low doses, highlighting its translational potential for gene therapy.